FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
Evaluation of Th9 lymphocytes in peripheral blood of rheumatoid arthritis patients and correlation with anti-tumor necrosis factor therapy: results from an in vitro pivotal study
2070PDF: 1003IL RUOLO DEI LINFOCITI TH9 NELL'ARTRITE REUMATOIDE E NELLA RISPOSTA AL TRATTAMENTO CON INFLIXIMAB.: 616 -
PO:02:025 | Real-World Comparative Effectiveness of Upadacitinib in Psoriatic Arthritis: Evaluation of Switching to Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors After First-Line Tumor Necrosis Factor Inhibitors Valentina Carlini1, Philip Mease2, William Tillett3, Xiaolan Ye4, Christopher Saffore4, Molly Edwards5, Isabel Truman5, Sophie Barlow5, Jayne Stigler4, Bhumik Parikh4, Daniel Aletaha6 | 1Abbvie srl Roma, Italy; 2University of Washington School of Medicine Seattle, United States Minor Outlying Islands; 3Department of Rheumatology, Royal National Hospital for Rheumatic Diseases Bath, United Kingdom; 4Abbvie Inc. North Chicago, United States Minor Outlying Islands; 5Adelphi Real World Bollington, United Kingdom; 6Division of Rheumatology, Department of Medicine, Medical University of Vienna, Vienna, Austria
26 -
S02:5 | Combined anti-IL-5/IL-5r and dupilumab therapy in eosinophilic granulomatosis with polyangiitis: a European retrospective study Miriam Guerini1, Pavel Novikov2, Roberto Padoan3, Georgina Espigol Frigolé4, Jan Willem Cohen Tervaert5, Vincent Grobost6, Laurent Guilleminault7, Jan Walter Schroeder8, Bernhard Hellmich9, Joana Martins Martinho10, Camillo Ribi11, Matthieu Groh12, Benjamin Terrier13. | 1IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy; 2Sechenov University, Moscow, Russia; 3University of Padova, Padova, Italy; 4Hospital Clinic, University of Barcelona, Barcelona, Spain; 5University of Alberta, Edmonton, Canada; 6CHU Estaing Clermont-Ferrand France; 7Toulouse University Toulouse France; 8ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy; 9Medius Kliniken Kirchheim-Teck Germany; 10ULS Santa Maria, Lisbon, Portugal; 11Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 12Hopital Foch, Suresnes, France; 13Service de Medecine interne, Hopital Cochin, AP-HP, Paris, France.
194 -
PO:02:021 | Sustained Improvements with Bimekizumab in Pain, Morning Stiffness, Fatigue, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 3-Year Results from Two Phase 3 Studies Victoria Navarro-Compán1, Uta Kiltz2|3, Philip J Mease4, Maureen Dubreuil5, Karl Gaffney6, Atul Deodhar7, Christine De La Loge8, Diana Voiniciuc9, Jason Coarse10, Ilaria Spadafora11, Helena Marzo-Ortega12 | 1La Paz University Hospital, IdiPaz, Department of Rheumatology Madrid Spain; 2Ruhr-University Bochum Bochum Germany; 3Rheumazentrum Ruhrgebiet Herne, Germany; 4Department of Rheumatology, Swedish Medical Center and Providence St. Joseph Health and University of Washington Seattle, USA; 5Boston University School of Medicine, Department of Rheumatology Boston, USA; 6Norfolk and Norwich University Hospital NHS Trust, Department of Rheumatology Norfolk, United Kingdom; 7Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases Portland, USA; 8UCB Brussels, Belgium; 9UCB Slough, United Kingdom; 10UCB Morrisville, USA; 11UCB Milan, Italy; 12NIHR Leeds Biomedical Research Centre, University of Leeds Leeds, United Kingdom
26 -
PO:01:014 | Differential inflammatory responses of CD14+ and CD14– synoviocytes in psoriatic arthritis: implications for pathogenesis and targeted therapies Monia Maccaferri1, Monica Montanari2, Francesco Zambianchi3|4, Carlo Salvarani1|5, Elisa Pignatti1|4 | 1Dipartimento CHIMOMO; 2Dipartimento di Scienze e Vita; 3Dipartimento SMECHIMAI Università di Modena e Reggio Emilia; 4Azienda Ospedaliero Universitaria di Modena; 5Struttura Complessa di Reumatologia, Azienda Unità Sanitaria Locale di Reggio Emilia-IRCCS, Italy
157 -
PO:07:103 | Tocilizumab use in patients with rheumatoid arthritis and malignancy: a monocentric experience Vittorio Dibenedetto1|2|3, Nicola Farina1|2, Nicola Boffini1|2, Alessandro Tomelleri1|2, Adriana Cariddi1|2, Elena Baldissera1|2, Marco Matucci-Cerinic1|2|3, Lorenzo Dagna1|2|3. | 1Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milano, Italy; 2Inflammation, Fibrosis and Ageing Intitiative INFLAGE, IRCCS San Raffaele Hospital, Milano, Italy; 3Vita-Salute San Raffaele University, Milano, Italy.
144 -
PO:01:011 | Achievement of Remission Defined by Absence of Objective Signs of Inflammation Versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies Lianne S Gensler1, Helena Marzo-Ortega2, Vanessa Taieb3, Diana Voiniciuc4, Alexander Marten5, George Stojan6, Mindy Kim6, Paolo Marsico7, Martin Rudwaleit8 | 1Department of Medicine/Rheumatology, University of California San Francisco, USA; 2NIHR Leeds Biomedical Research Centre, University of Leeds Leeds, United Kingdom; 3UCB Colombes, France; 4UCB Slough, United Kingdom; 5UCB Monheim am Rhein Germany; 6UCB Atlanta, USA; 7UCB Milan, Italy; 8University of Bielefeld, Klinikum Bielefeld Bielefeld Germany
27 -
PO:35:223 | Biologic therapy for sustained remission in eosinophilic myocarditis: real-world evidence from a tertiary center experience Federica Davanzo1, Caterina Menghi2, Andrea Silvio Giordani2, Anna Baritussio2, Federico Scognamiglio2, Cristina Vicenzetto2, Luca Iorio1, Renzo Marcolongo2, Cristina Basso3, Andrea Doria1, Roberto Padoan1, Alida Linda Patr Caforio2 | 1Rheumatology Unit, Department of Medicine, University of Padua Padova, Italy; 2Cardiology Unit, Department of Cardiac, Vascular, Thoracic Sciences and Public Health, University of Padua Padova, Italy; 3Cardiovascular Pathology, Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua Padova, Italy
28 -
PO:22:029 | Impact of mepolizumab on idiopathic hypereosinophilic syndromes: analysis of a monocentric retrospective cohort Jacopo Mora1, Francesca Regola1, Paola Toniati2, Ilaria Cavazzana1, Franco Franceschini1. | 1ASST Spedali Civili e Università degli Studi di Brescia, Brescia, Italy; 2ASST Spedali Civili di Brescia, Brescia, Italy.
134 -
PO:04:046 | Achieving Early Clinical Response was Associated with Cumulative Benefits on Disease Impact up to 2 Years in Patients with Active Psoriatic Arthritis Treated with Bimekizumab William Tillett1|2, Joseph F Merola3, Iain B Mcinnes4, Kenneth B Gordon5, Richard B Warren6, Patrick Healy7, Jérémy Lambert8, Heather Edens9, Barbara Ink10, Paola Volpe11, Laure Gossec12 | 1Royal National Hospital of Rheumatic Diseases Bath, United Kingdom; 2Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath Bath, United Kingdom; 3Department of Dermatology and Department of Medicine, Division of Rheumatology, Utah Southwestern Medical Center Dallas, USA; 4College of Medical Veterinary and Life Sciences, University of Glasgow Glasgow, United Kingdom; 5Department of Dermatology, Medical College of Wisconsin Milwaukee, USA; 6Northern Care Alliance, NHS Foundation Trust and Manchester Academic Health Science Centre, University of Manchester Manchester, United Kingdom; 7UCB Morrisville, USA; 8UCB Colombes, France; 9UCB Smyrna, USA; 10UCB Slough, United Kingdom; 11UOC Reumatologia, P.O. Spirito Santo Pescara, Italy; 12Sorbonne Universite and Pitie-Salpetriere Hospital Paris, France
35 -
PO:35:234 | Sustained Vasculitis Quiescence and CS Reduction with Mepolizumab 100 mg Francesca Mascia1, Angelo Fassio2, Marco Zurlo1, Davide Chesini3, Francesco Pollastri2, Giovanni Adami2, Davide Gatti4, Maurizio Rossini4, Matteo Maule5, Gianentrico Senna1, Marco Caminati1 | 1University of Verona - Allergology and Clinical Immunology Verona, Italy; 2Policlinico G. B. Rossi - Rheumatology Verona, Italy; 3University of Verona - Faculty of Medicine and Surgery Verona, Italy; 4University of Verona - Rheumatology Verona, Italy; 5Policlinico G. B. Rossi - Allergology and Clinical Immunology Verona, Italy
21 -
PO:01:004 | Real-world retention of IL-17 inhibitors in psoriatic arthritis: impact of prior IL-17 exposure across multiple treatment lines in the “BIRRA” multicentre cohort Valentino Paci1, Alarico Ariani2, Eleonora Celletti3, Alberto Lo Gullo4, Camilla Mazzanti5, Valeria Nucera6, Natalia Mansueto7, Rosalba Caccavale8, Patrizia Del Medico9, Antonella Farina10, Palma Scolieri11, Cecilia Giampietro12, Olga Addimanda13, Riccardo Bixio14, Maddalena Larosa15, Viviana Ravagnani16, Federica Lumetti17, Aldo Biagio Molica Colella17, Elena Bravi17, Rosetta Vitetta17, Bernd Raffeiner17, Gilda Sandri18, Rosario Foti19, Simone Parisi20, Michele Maria Luchetti Gentiloni1, Gianluca Moroncini1. | 1Clinical Medicine, Department of Clinical and Molecular Sciences, Marche Polytechnic University, AOU delle Marche, Ancona, Italy; 2Internal Medicine and Rheumatology Unit, University Hospital of Parma, Parma, Italy; 3Rheumatology Unit, Clinica Medica Institute, Ospedale SS. Annunziata di Chieti, G.d'Annunzio University of Chieti, Chieti, Italy; 4Rheumatology Unit, ARNAS Garibaldi di Catania, Catania, Italy; 5Center for the Diagnosis and Therapy of Autoimmune Rheumagological Diseases, Ospedale Santa Rosa, ASL Viterbo Viterbo Italy; 6Rheumatology Outpatient Unit, ASL Novara, Novara, Italy; 7Ambulatori di Reumatologia ASL1 Liguria, Imperia Hospitall Imperia Italy; 8Department of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Polo Pontino, Roma, Italy; 9Rheumatology outpatient clinic - Internal Medicine Unit, Civitanova Marche Hospital, Civitanova Marche, Italy; 10Internal Medicine Unit, Rheumatology outpatient clinic, Ospedale A. Murri di Fermo, Fermo, Italy; 11Department of Medical Specialties, Nuovo Regina Margherita Hospital, Rome, Roma, Italy; 12Rheumatology Outpatient Clinic, Azienda ULSS 6 Euganea, Padova, Padova, Italy; 13Rheumatology Unit, Azienda Unità Sanitaria Locale di Bologna -- Policlinico S.Orsola- AOU di Bologna, Bologna, Italy; 14Rheumatology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy; 15Division of Rheumatology - Medical Specialties Department, Ospedale La Colletta-Azienda Sanitaria Locale 3, Genova, Italy; 16Rheumatology Unit, Santa Chiara Hospital APSS Trento Italy; 17BIRRA - BIologic Retention Rate in chronic Arthritis - study group, Parma, Italy; 18Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy; 19Rheumatology Unit, Policlinico San Marco Hospital, Catania, Italy; 20Rheumatology Department, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
214 -
PO:19:284 | Use of anakinra during pregnancy and breastfeeding in women with recurrent pericarditis: a case series Lucia Trotta1, Marco Quartarone1, Francesco Cavaleri1, Ruggiero Mascolo1, Massimo Imazio3, Vartan Mardygan2, Andreja Cerne Cercek4, Anne-Marie Claveau2, Ludovico Luca Sicignano5, Massimo Pancrazi1, Alida Caforio6, Andrea Silvio Giordani6, Serdal Ugurlu7, Alessandro Andreis8, Valentino Collini3, Enrico Tombetti9, Antonio Brucato9 | 1Department of Internal Medicine, ASST Fatebenefratelli-Sacco, Milan, Italy; 2Division of Cardiology, Department of Medicine, Jewish General Hospital, Montréal, Québec, Canada; 3Cardiology, Cardiothoracic Department, University Hospital Santa Maria della Misericordia, Udine, Italy; 4Department of Cardiology, University Medical Centre Ljubljana, Ljubljana, Slovenia; 5Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 6Division of Cardiology, Centro Gallucci, University of Padova-Policlinico, Padova, Italy; 7Division of Rheumatology, Department of Internal Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey; 8University Cardiology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy; 9Department of Biomedical and Clinical Sciences, Fatebenefratelli Hospital, University of Milan, Milan, Italy
44 -
PO:37:260 | Mepolizumab in the treatment of patients with eosinophilic granulomatosis with polyangiitis: real-life experience from a single-center cohort Eleonora Bruschi1, Fabrizio Angeli1, Alessandro Belotti Masserini1, Stefania Bertocchi1, Silvia Breda1, Elide Lupi1, Valeria Rossi1, Tania Ubiali1, Massimiliano Limonta1 | 1ASST Papa Giovanni XXIII Bergamo Italy
154 -
PO:03:033 | Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials Irene E Van Der Horst-Bruinsma1, Matthew A Brown2, Floris A Van Gaalen3, Nigil Haroon4, Lianne S Gensler5, Alexander Marten6, Myriam Manente7, George Stojan8, Thomas Vaux9, Katy White9, Atul Deodhar10, Nicola Boffini11, Martin Rudwaleit12 | 1Department of Rheumatology, Radboud University Medical Centre Nijmegen, The Netherlands; 2Genomics England London, United Kingdom; 3Department of Rheumatology, Leiden University Medical Center Leiden, The Netherlands; 4Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto Toronto, Canada; 5Department of Medicine/Rheumatology, University of California San Francisco, USA; 6UCB Monheim am Rhein Germany; 7UCB Braine-lAlleud, Belgium; 8UCB Atlanta, USA; 9UCB Slough, United Kingdom; 10Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University Portland, USA; 11IRCCS Ospedale San Raffaele Milan, Italy; 12Klinikum Bielefeld, University of Bielefeld, Bielefeld, Germany
23 -
PO:35:219 | Real-world effectiveness of mepolizumab on gastrointestinal involvement in eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a multicentre retrospective study Alessia Gatti1, Francesca Regola1, Giulia Fontana1, Mario Addrea Piga2, Gianluca Moroncini2, Palma Carlucci3, Angelo Vacca3, Paolo Delvino4, Enrico Heffler5, Emanuele Nappi5, Jakub Moll6, Laura Losappio6, Jan Schroeder6, Federica Davanzo7, Roberto Padoan7, Edoardo Conticini8, Paolo Cameli8, Greta Pacini9, Alvise Berti9, Lorenzo Vrola10, Paola Tomietto10, Luca Quartuccio11, Jan Willem Cohen Tervaert12, Sabrina Arnold13, Peter Lamprecht13, Florence Roufosse14, Ilaria Cavazzana1, Franco Franceschini1, Giacomo Emmi15, Paola Toniati1. | 1Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Italy, Brescia, Italy; 2Università Politecnica delle Marche and Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy, Ancona, Italy; 3Section of Internal Medicine 'Guido Baccelli', DiMePRe-J, University of Bari 'Aldo Moro', Bari, Italy, Bari, Italy; 4Rheumatology Unit, IRCCS San Gerardo dei Tintori, Monza, Italy Monza Italy; 5Department of Biomedical Sciences, Humanitas University and Personalized Medicine, Asthma and Allergy IRCCS Humanitas, Milano, Italy; 6Division of Allergy and Clinical Immunology, ASST GOM Niguarda, Milan, Italy, Milano, Italy; 7Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, Padova, Italy; 8University of Siena, Siena, Italy, Siena, Italy; 9Santa Chiara Hospital and University of Trento, Unit of Rheumatology, Trento, Italy Trento Italy; 10UCO Medicina Clinica, ASUGI, Cattinara Teaching Hospital, Trieste, Italy, Trieste, Italy; 11Division of Rheumatology, Department of Medicine DMED, University of Udine, Udine, Italy, Udine, Italy; 12University of Alberta, Edmonton, Alberta, Canada and Maastricht University, Maastricht, The Netherlands Maastricht The Netherlands; 13Department of Rheumatology and Clinical Immunology, University of Lübeck, Lübeck, Germany Lubeck Germany; 14Department of Internal Medicine, Hôpital Universitaire de Bruxelles - Erasme, Université Libre de Bruxelles, Belgium Brussels Belgium; 15Clinical Medicine and Clinical Immunology and Rheumatology Unit Cattinara University Hospital and University of Trieste, Trieste, Italy.
193
1 - 31 of 31 items
